Degevma (denosumab-adet)

Where it stands

Degevma (denosumab-adet), a biosimilar from Teva, is recorded as approved in both the US and the EU. The FDA approval is dated 2026-09-25 under BLA761481, with Teva Pharmaceuticals, Inc. as the company and an injectable presentation. The EU approval is an European Commission decision dated 2025-11-17, with the marketing authorisation held by Teva GmbH. In the EU the product is listed as Degevma (denosumab).

On the records, the EU decision came before the US approval, by roughly ten months. The records give no CHMP opinion date, so the timing of the EU scientific opinion cannot be stated here. The records also leave the therapeutic area and the approved indication blank. This analysis therefore cannot say which uses are authorised in either region, or whether the US and EU indications match.

The records also list another US product with the same substance, Ponlimsi, as approved. They do not say who markets it, whether it is also a biosimilar, or how it relates to Degevma.

Regulatory pathway and designations

Degevma carries the Biosimilar designation in both regions. In the US, a biosimilar is approved on a demonstration of high similarity to an already-licensed reference biologic. The BLA number, 761481, is consistent with that biologics licensing route. The records do not name the reference product or describe the data package, and they do not say whether the FDA has designated the product as interchangeable.

In the EU, the records show a centralised-style outcome: a European Commission decision, with the marketing authorisation granted to Teva GmbH. The CHMP opinion that normally precedes such a decision is not recorded. The EU entry also carries an Additional monitoring flag, discussed below.

Differences in the US and EU marketing-authorisation holder entities (Teva Pharmaceuticals, Inc. and Teva GmbH) reflect regional structure. The records do not indicate any other significance.

Safety and pharmacovigilance

The only safety-related item in the records is the EU Additional monitoring status. This status, usually shown by a black inverted triangle in product information, means the product is subject to intensified safety surveillance. It is often applied to newly authorised products. Healthcare professionals and patients are encouraged to report suspected adverse reactions. It does not by itself indicate a specific safety concern.

The records contain no information on the safety profile, warnings, risk-management commitments, post-authorisation studies or US labelling. Nothing can be said here about specific risks or REMS-type requirements, and a reader should consult the current EU product information and US prescribing information for those details.

What to watch

The first gap to close is the missing indication and therapeutic area. These determine the product's competitive and clinical scope, and the authorised uses should be checked against the EU and US labels. The same applies to the reference product and to any interchangeability status, none of which are in the records.

Next, watch for the US launch and any presentation or labelling details. The records give no launch timing, and the record of the existing Ponlimsi approval suggests more than one product with this substance on the US market. Neither pricing nor market-entry plans are given, and none are inferred here.

On pharmacovigilance, the practical point is the EU Additional monitoring status. Its removal or continuation would be reflected in later EU product information updates, and any such change would need to be confirmed against official sources.